We Partner 4 Research

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

Purpose

Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)

Condition

Liver Neoplasms

Eligibility

Eligible Ages: All ages
Eligible Genders: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Patients with confirmed diagnosis of unresectable HCC - Physician-initiated decision to treat with regorafenib (prior to study enrollment)

Exclusion Criteria

Participation in an investigational program with interventions outside of routine clinical practice - Past treatment with regorafenib

Study Design

Phase
Study Type: Observational
Observational Model: Cohort
Time Perspective: Prospective

Arm Groups

Arm	Description	Assigned Intervention
uHCC patients treated with regorafenib	Patients with a confirmed diagnosis of uHCC and for whom a decision to treat with regorafenib has been made (by the treating physician)	Drug: Regorafenib (Stivarga, BAY73-4506) As per the treating physicians discretion

More Details

Status: Completed
Sponsor: Bayer

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.